Friday, October 30, 2026

QuantumScape Stock Bullish By 12% So Far Today

QuantumScape Stock Bullish By 12% So Far Today

QuantumScape Corp. (NYSE: QS) posted an astounding increase of 12.7% to $58.56 on Thursday after two consecutive trading days of gains and coinciding with an overall rise in New York Stock Exchange trading by 0.07% to $14,429.90 after five straight sessions of gains. This is a considerable achievement for the San Jose based company.

QuantumScape's Specialization

QuantumScape of San Jose, which specializes in developing and commercializing solid-state lithium-metal batteries specifically for electric vehicles, appears to be on an upswing. Their earnings per share over the last year was 0.97. This points to their successful operation and penetration into the market geared towards environmentally friendly technology.

Growth Forecasts and Market Indicators

QuantumScape's growth forecasts are optimistic, with estimates for current and subsequent quarters at 9.1% and 22.2%, respectively. Investors should keep in mind that according to the stochastic oscillator - a key indicator of overbought/oversold situations - QuantumScape shares are currently considered overbought. It is important for interested investors to be aware of such market indicators.

Recent Volatility in QuantumScape’s Stock

Recently, this stock has experienced dramatic fluctuations with intraday changes averaging 2.73% last week, monthly increases averaging 1.62% and quarterly rises at 3.59% respectively. Notably, volatility peaked at 2.87% for week 1, 3.288% and 3.589% during month 1 and quarter 1, respectively. These movements indicate a highly changeable and dynamic market presence.

Trading Volume

Notably, QuantumScape's trading volume has exceeded expectations significantly - at 48,400,828 the last recorded volume was an impressive 745 252.55% over its typical volume of 5,72 6 18180! Investors should closely follow this stock for potential opportunities while being wary of its volatility.

More news about QuantumScape (QS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com